cholangiocarcinoma
Oncology · 2024–2025
3decisions
2medicines
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| futibatinib Treatment of patients with locally advanced or metastatic cholangiocarcinoma who have previously progressed on systemic therapy and have a FGFR2 fusion or… | Mar 2025 | Not recommended | input received |
| futibatinib Locally advanced or metastatic cholangiocarcinoma in patients with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed… | Nov 2025 | Recommended | input received Session Addendum Cancers Australia · Pancare Foundation · Liver Foundation |
| ivosidenib Treatment of locally advanced or metastatic cholangiocarcinoma (CCA) in patients with IDH1 R132 variant whose disease has progressed on at least one prior line… | Jul 2024 | Not recommended | input received |
Who spoke
Session Addendum Cancers Australia · Pancare Foundation · Liver Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.